CAMP4 Therapeutics Corporation (NASDAQ:CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE:GSK).
The collaboration aims to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.
Under the terms of the agreement, CAMP4 will receive a $17.5 million cash upfront payment.
Also Read: FDA Approves GSK’s Drug, Targets Severe Asthma With Two Doses Per Year
Additionally, CAMP4 has the potential to receive additional payments for certain development and commercial milestones, in addition to tiered royalties on future product sales.
CAMP4 will utilize its proprietary RAP Platform to identify regRNAs controlling the expression of multiple gene targets and generate regRNA-targeting ASO candidates that amplify target gene expression for potential development.
GSK will be responsible for the further development and commercialization of ASO drug candidates identified through the collaboration.
In October, CAMP4 Therapeutics initiated toxicology studies conducted for its lead product candidate, CMP-SYNGAP-01.
These studies will support the company’s planned submission of a clinical trial application, which could enable the initiation of a first-in-human Phase 1/2 trial in SYNGAP1-related disorders as early as the second half of 2026.
Analyst Take
William Blair views the collaboration as another source of third-party RegRNA platform validation alongside the BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) collaboration in therapeutic areas outside the core focus of the company’s wholly owned rare-disease franchise.
William Blair reiterates an Outperform rating on Camp.
“We view investment from GSK as supportive of the notion that those results were confined to difficulties in data collection, separate from potential lack of platform activity, and we are particularly excited about the company’s wholly owned CMP-002 set to enter the clinic in the second half of 2026 in SYNGAP-dEEs. We reiterate our Outperform rating on Camp4,” William Blair wrote on Thursday.
Price Action: CAMP stock is down 0.16% at $6.20 at the last check on Friday.
Read Next:
Photo via Shutterstock
Recent Comments